Comparative efficiency of Proproten-100 during the therapy of patients with alcoholism in the stage of therapeutic remission.
An open comparative clinical study evaluated the efficiency of Proproten-100 in reliving affective, somatovegetative, behavioral, and cognitive post-withdrawal disorders and manifestations of primary pathological alcohol addiction in patients with alcohol dependence in the stage of therapeutic remission. We compared the efficiency of Proproten-100 and standard symptomatic drugs. The preparation possessed anxiolytic, antidepressant, and vegetostabilizing properties, produced a moderate soporific effect, and had no sedative activity in patients with dysphoric depressions and psychopathic disorders. Proproten-100 was more effective during the therapy of patients with anxious and wistful depressions. Proproten-100 increased the contents of IgG and natural antibodies against S100 protein in the blood from patients. The preparation did not cause side effect or development of tolerance. Proproten-100 has psychotropic properties and holds much promise for long-term treatment of patients with alcohol dependence to reduce the incidence of recurrences.
Bokhan
N A
NA
Institute of Mental Health, Tomsk Research Center, Siberian Division of the Russian Academy of Medical Sciences.
Abolonin
A F
AF
Krylov
E N
EN
Vetlugina
T P
TP
Ivanova
S A
SA
Epstein
O I
OI
D000328:Adult; D000437:Alcoholism / Q000188:drug therapy*; D014151:Anti-Anxiety Agents / Q000276:immunology / Q000627:therapeutic use*; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009418:S100 Proteins / Q000276:immunology*; D016896:Treatment Outcome
D014151:Anti-Anxiety Agents; D000906:Antibodies; D000928:Antidepressive Agents; D009418:S100 Proteins